CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $12.50 per share, before underwriting discounts and commissions. In addition, Syros has granted the underwriters a 30-day option to purchase up to 600,000 additional shares of common stock from Syros at the public offering price, less the underwriting discount and commissions, to cover over-allotments, if any. All of the shares are being offered by Syros Pharmaceuticals. The Company’s shares are scheduled to begin trading on The NASDAQ Global Select Market on June 30, 2016 under the ticker symbol “SYRS.” The offering is expected to close on July 6, 2016, subject to customary closing conditions.
Cowen and Company and Piper Jaffray & Co. are acting as joint book-running managers for the offering. JMP Securities is acting as lead manager for the offering, and Wedbush PacGrow is acting as co-manager for the offering.
A registration statement relating to these securities has been filed with, and was declared effective by, the Securities and Exchange Commission on June 29, 2016. Copies of the registration statement can be accessed by visiting the Securities and Exchange Commission website at www.sec.gov.
This offering is being made only by means of a prospectus. A preliminary prospectus describing the terms of the offering has been filed with the Securities and Exchange Commission and forms a part of the effective registration statement. A copy of the final prospectus relating to the offering will be filed with the Securities and Exchange Commission, and may be obtained, when available, from Cowen and Company LLC, c/o Broadbridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, by telephone at (631) 274-2806 or by fax at (631) 254-7140, and from Piper Jaffray & Co., by mail at Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924 or by email at prospectus@pjc.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
About Syros Pharmaceuticals
Syros Pharmaceuticals is
pioneering the understanding of the non-coding region of the genome to
advance a new wave of medicines that control expression of
disease-driving genes. Syros has built a proprietary platform that is
designed to systematically and efficiently analyze this unexploited
region of DNA in human disease tissue to identify and drug novel targets
linked to genomically defined patient populations.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160629006518/en/
Media Contact:
Ten Bridge Communications, Inc.
Naomi
Aoki, 617-283-4298
naomi@tenbridgecommunications.com
or
Investor
Contact:
Stern Investor Relations, Inc.
Jesse Baumgartner,
212-362-1200
jesse@sternir.com
Source: Syros Pharmaceuticals
Released June 29, 2016